How is it baseless? Let's face it Isradapine will be good for the revenue # but I think I can speak for everyone in saying that we're not here for an extra 200k a quarter in revenue. Until some investors/traders get the news they're looking for, then they will play the range on the charts accordingly. That news is most likely more trial results/big partner news/NDA filing late this year.
For the past 4 months the range has been low .30's to high .40's. How's that for rationalization?
News 
Market Data 
Discover 
AI
